Trial results

$MLTX — SLK (sonelokimab)

MoonLake Immunotherapeutics (MLTX) SLK (sonelokimab): trial results in Hidradenitis suppurativa (HS), 2027.

Research by Catalyst Intel

The catalyst

"We expect to complete the VELA-TEEN clinical trial in the fourth quarter of 2026 and to announce final topline results in the first quarter of 2027."

— MoonLake Immunotherapeutics, 10-Q filed 2026-11-04 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

MLTX-SLKSONELOKIM-2026

Company

MoonLake Immunotherapeutics

Kind

Trial results

Indication

Hidradenitis suppurativa (HS)

Window

2027-01-01 – 2027-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.